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Abstract  
The MITF-low melanoma transcriptional signature is predictive of poor outcomes for patients 
but little is known about its biological significance and animal models are lacking. Here, we 
used zebrafish genetic models with low activity of Mitfa (MITF-low) and established that the 
MITF-low state is causal of melanoma progression and a predictor of melanoma biological 
subtype. MITF-low zebrafish melanomas resembled human MITF-low melanomas and were 
enriched for stem and invasive (mesenchymal) gene signatures. MITF-low activity coupled with 
a p53 mutation was sufficient to promote superficial growth melanomas, while BRAF
V600E
 
accelerated MITF-low melanoma onset and further promoted the development of MITF-high 
nodular growth melanomas. Genetic inhibition of MITF activity led to rapid regression; 
recurrence occurred following reactivation of MITF. At the regression site, there was minimal 
residual disease that was resistant to loss of MITF activity (termed MITF-independent cells) 
with very low-to-no MITF activity or protein. Transcriptomic analysis of MITF-independent 
residual disease showed enrichment of mesenchymal and neural crest stem cell signatures 
similar to human therapy-resistant melanomas. Single-cell RNA-seq revealed MITF-
independent residual disease was heterogeneous depending on melanoma subtype. Further, 
there was a shared subpopulation of residual disease cells that was enriched for a neural crest 
G0-like state that pre-existed in the primary tumor and remained present in recurring 
melanomas. These findings suggest that invasive and stem-like programs coupled with cellular 
heterogeneity contribute to poor outcomes for MITF-low melanoma patients, and that MITF-
independent subpopulations are an important therapeutic target to achieve long-term survival 
outcomes. 
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Significance 
This study provides a useful model for MITF-low melanomas and MITF-independent cell 
populations that can be used to study the mechanisms that drive these tumors as well as 
identify potential therapeutic options.  
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Introduction  
Melanoma is the most lethal form of skin cancer, and its incidence continues to rise rapidly. 
Despite the significant progress in targeted therapy against BRAF mutations and MEK activity, 
and in immune therapy, most patients with metastatic melanoma still succumb to the disease 
because they do not respond to therapy or they develop drug resistance (1). Genetic mutations 
define subgroups of melanoma (BRAF, RAS or NF1 mutated, or Triple-Wild type (WT)) that 
can help predict a positive response to targeted therapy, however overall this genomic 
classification cannot predict patient survival (2).   
In contrast, gene expression profiling of melanomas has revealed transcription-based 
melanoma subtypes that have significance for disease outcome and may be important for 
patient care (3). The TCGA melanoma dataset revealed three transcriptionally distinct 
subtypes that are enriched for immune genes, for keratinocyte genes, or have low expression 
of the melanocyte-inducing transcription factor (MITF) and its targets as well as high 
expression of neuronal genes (called the MITF-low signature) (2).  
The TCGA MITF-low signature in primary and metastatic melanomas shares over 75% overlap 
with a MITF-low proliferation transcriptional subtype identified in the Lund dataset of stage IV 
metastatic melanomas (4). The TCGA MITF-low and Lund MITF-low proliferation groups are 
further found in the primary (Leeds), stage III (Lund) and metastatic (Bergen) transcriptome 
melanoma datasets (5-7). Together, these data support the concept that MITF-low 
transcriptional activity defines a melanoma biological subtype (8). Importantly, outcomes for 
patients with melanomas that express the TCGA MITF-low signature or the Lund MITF-low 
proliferative signature genes are amongst the poorest for survival and metastasis (8). However, 
whether the MITF-low signature is simply a marker for poor outcomes or whether it is causative 
remains an open question.  
Here, we use zebrafish genetics coupled with analysis of human melanoma transcriptomes to 
determine the biological significance of the MITF-low classification, and reveal a pre-existing 
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melanoma cell subpopulation that is resistant to loss of MITF activity and has very low-to-no 
MITF activity toward its target genes (termed MITF-independent cells). These cells remain at 
the site of residual disease and could be an important drug target.  
 
Materials and methods  
Husbandry 
Zebrafish were maintained in accordance with UK Home Office regulations, UK Animals 
(Scientific Procedures) Act 1986, under project license 70/8000 and P8F7F7E52. All 
experiments were approved by the Home office and AWERB (University of Edinburgh Ethics 
Committee). 
Zebrafish melanoma models   
Zebrafish were genotyped using DNA extracted from fin clipped tissue by PCR to establish the 
mutant allele status tp53
M214K
 or mitfa-BRAF
V600E
 and grown in temperature-controlled systems 
as described (9). Briefly, for melanoma induction, or recurrence, fish were transferred to glass 
tanks at room temperature (24-26°C), while for melanoma regression fish were transferred to 
tanks with heaters that kept the temperature at 32°C.  
Histology 
Fish samples were collected, fixed and processed as described (9). The detailed method is 
described in Supplementary Material and Methods. Antibodies and their dilutions are listed in 
Supplementary Table S1.  
Low number and single cell RNA-seq library preparation 
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For low cell number and single cell RNA-Seq, the Smart-seq2 protocol was used with minor 
modifications as described previously (10) and detailed in Supplementary Materials and 
Methods.  
Read mapping and differential gene expression analysis of bulk and low number RNA-
seq 
Reads were aligned to the Ensembl Danio rerio reference genome version GRCz11 (Ensembl 
V92, 20178) that included coding sequences for EGFP and BRAF
V600E
 using STAR (V 2.5.1b, 
(11). For quality control and pre-processing, quantification of mapped reads per gene was 
calculated using HTseq (12). Genes that were not expressed in any cells were excluded. Data 
were not normalized for any variable based on histological evaluation. The raw read counts 
were loaded in the R Deseq2 package (V 1.20.0, (13). For bulk samples, genes with fewer than 
10 reads across the samples were excluded. Quality control exclusion criteria for low cell 
number RNA-seq samples were the following: samples with fewer than 100,000 unique-
mapped reads and fewer than 1,000 genes detected (minimum one read per gene) were 
excluded. For differential gene expression analysis, genes displaying fewer than 10 counts 
across all samples for bulk RNA-seq or that did not express with at least 1 count in a minimum 
of 3 samples for low number RNA-seq were excluded.  
Single cell RNA-seq analysis 
Single cell RNA-seq analysis was performed using adapted pipeline from Lun et al. (14). 
Detailed description of the analysis is found in Supplementary Materials and Methods.  
Pathway analysis 
Genes upregulated from DESeq2 (bulk samples), or scDE (single cell) were selected based on 
FDR<0.05 and ranked by Log2FC (Log2FC>0) for input to the R ClusterProfiler package (15). 
To examine pathway over-representations based on literature available datasets (abbreviated 
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by L: Supplementary Table S2, all genes have been manually converted to zebrafish 
orthologues using zfin.org database), or using KEGG (K:) and GO-BP (G:) databases. 
Pathways with p.adj<0.05 (hypergeometric test, BH adjusted) were considered to be 
significant, listed in Supplementary tables with subsets visualized using dot-plots. 
Gene set functional enrichment analysis (GSEA) (16) identified enriched pathways at 
FDR<0.05 (Kolmogorov–Smirnov test). The matrix of all read counts was used to compare 
against literature-based datasets (Supplementary Table S2) using gene set permutation 
settings. FDR values and leading-edge genes of enrichment plots shown in Figures are listed 
in Supplementary Table S3.  
qRT-PCR 
Detailed method is described in Supplementary Materials and Methods with primers listed in 
Supplementary Table S4.  
Data availability: RNA-seq data are deposited in the GEO database (GSE130037 and 
GSE136900).  
For additional Materials and Methods, please see Supplementary Information. 
 
Results 
MITF-low activity co-operates with p53 mutations and BRAF
V600E 
in melanoma   
The MITF gene is highly conserved and in zebrafish there are two orthologous mitf genes (a 
and b) whereby mitfa is required for the development of all body melanocytes (17). A genetic 
temperature sensitive mitfa mutation (mitfa
vc7
) in zebrafish has enabled us to test the impact of 
altering MITF activity in development and show that low MITF activity co-operates with 
BRAF
V600E 
in melanomagenesis (9,18,19). The conditional mitfa
vc7
 mutant allele results from a 
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single nucleotide T-to-A mutation in intron 6 that disrupts splicing in a temperature sensitive 
manner (18,20). Analysis of the splicing variants of mitfa
vc7
 indicates that at permissive 
temperatures (25ºC) lower levels of wild type mitfa RNA are generated (defined as a MITF-low 
state), and that these transcripts are further reduced with increasing water temperatures (Fig. 
1A) (9,20). Thus, this conditional control of mitfa RNA enables us to regulate wild type mitfa 
expression in zebrafish development and cancer.   
In the TCGA data, an MITF-low transcriptional signature is found in 18% of cutaneous 
melanomas and across all four TCGA cutaneous melanoma genomic groups (Fig. 1B). TP53 
(p53) is frequently mutated in human melanoma (18% of cutaneous melanoma; TCGA), and 
these mutations co-operate with BRAF
V600E
 mutations to promote melanoma in zebrafish and 
mouse models (21,22). We aimed to model the MITF-low transcriptional state using genetic 
mutation combinations present in MITF-low melanomas in patients. We explored the human 
melanoma genetic and transcriptomic TCGA dataset and found TP53 mutations or low levels 
of TP53 expression in BRAF mutant and non-BRAF-mutant melanomas, including a minor 
subset that have the MITF-low transcriptional signature (Fig. 1B). To test the potential for p53 
mutations to co-operate with MITF-low activity in nevi and melanoma we generated zebrafish 
homozygous for mitfa
vc7
 and tp53 (p53
M214K
) mutations. The impact of the conditional mitfa
vc7 
activity on zebrafish stripe formation can be seen in Fig. 1C (left panels) whereby zebrafish 
grown at <25ºC (MITF-low activity state) develop fewer melanocytes in a stripe pattern while 
animals grown at 32ºC lack sufficient functional MITF activity to develop body melanocytes.   
Strikingly, we found that the mitfa
vc7
;p53
M214K
 animals developed large darkly pigmented 
melanocyte lesions by 9 months that progressed into melanoma with 73% incidence (n= 
94/129; Fig. 1C, D). These data reveal an unexpected co-operation between MITF-low activity 
and p53
 
mutations in melanoma initiation that is independent of MAPK activation. To address 
the impact of the BRAF
V600E
 mutation on mitfa
vc7
;p53
M214K
 zebrafish, we crossed the 
mitfa
vc7
;p53
M214K
 zebrafish to zebrafish expressing human BRAF
V600E 
from the mitfa promoter 
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(23). This promoter is not regulated by Mitfa protein levels, and thus BRAF
V600E 
expression is 
not altered by levels of Mitfa in the mitfa
vc7 
mutant (9).  BRAF
V600E 
dramatically accelerated the 
onset of melanoma, and gave rise to melanomas with both superficial growth and exophytic 
nodular growth patterns, and could be either pigmented or unpigmented (Fig. 1C-E). Taken 
together these results reveal that BRAF
V600E
, MITF-low
 
activity and
 
p53
 
mutations have an 
independent and co-operative impact on melanoma initiation and growth.  
Superficial and nodular growth melanomas differ in mode of invasion  
Next, we examined the pathology of the melanoma subtypes. Histological examination showed 
all tumors to be highly cellular and express Melan A (Supplementary Fig. S1A, B; n=15/15).   
Melanomas from the mitfa
vc7
;p53
M214K
 fish originated from the skin, grew in a superficial growth 
pattern, and were highly invasive into the muscle, penetrating the tissue to deeper levels, 
around the internal organs and towards the spinal cord (Fig. 2A-C). We term these melanomas 
double superficial (DS) because they have two engineered genetic mutations and grow in a 
superficial growth pattern. The melanomas in the Tg(mitfa:BRAF
V600E
); mitfa
vc7
;p53
M214K
 fish 
grew in either a superficial or a highly proliferative nodular growth pattern (referred to as triple 
superficial (TS) or triple nodular (TN)) (Supplementary Fig. S1C, D). Both the superficial and 
nodular growth melanomas were highly invasive but they differed in the nature of invasion. We 
measured from the level of the background contour of the fish to the deepest invasive cell and 
found no difference between the superficial and nodular growth melanomas in invasion depth. 
In contrast, there was a marked difference in the mode of invasion: superficial growth 
melanomas showed a single-to-few cell wide stream of highly infiltrative cancer cells between 
muscle fibers, while nodular growth melanomas showed a more confluent invasive growth 
pattern often leading to deterioration of surrounding tissues (Fig. 2D-F). 
Notably, despite heavy pigmentation in the DS and TS tumors at the surface site, melanoma 
cells of the invasive region were unpigmented (Fig. 2A-C). DS
 
melanomas showed little to no 
activation of the MAPK-signaling pathway in the superficial part of the tumor, but the 
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unpigmented invasive compartments expressed high levels of phospho-ERK in a 
heterogeneous pattern (Fig. 2G, H). To relate this finding to human melanoma, we asked 
whether MAPK signaling pathways are associated with an increase in invasive properties in 
TCGA triple-WT melanomas. We found a significant positive correlation between the invasive 
signature genes and MAPK-signaling signature genes (Supplementary Fig. S1E) indicating 
that MAPK-signaling is associated with melanoma invasion in both zebrafish and human triple-
WT melanomas. This is consistent with the findings of Shain et al. (24) in which genetic and 
transcriptomic activation of the MAPK signaling pathway increases with disease progression. 
Melanoma subtypes cluster by genotype and directionality of growth 
To analyse the three melanoma models, we dissected the DS, TS and TN tumors from 
melanoma-bearing fish and performed bulk RNA-seq (Fig. 3A, Supplementary Fig. S2A-C). 
Principal component analysis divided the melanoma transcriptomes into three groups (Fig. 
3B). Along the PC1 axis, melanomas separated according to the direction of growth (superficial 
or nodular), and along the PC2 axis melanomas separated according to the presence or 
absence of BRAF
V600E
. Although pigmented nodular growth melanomas are found between the 
BRAF
V600E
 superficial growth and the BRAF
V600E
 unpigmented nodular growth melanomas in 
the PCA (Fig. 3B), they clustered together with BRAF
V600E
 unpigmented nodular growth 
melanomas by hierarchical clustering (Supplementary Fig. S3A). 
MITF transcriptional states distinguish superficial and nodular growth melanomas 
We quantified mRNA expression of mitfa between DS and TS superficial growth melanomas 
and found no significant difference in its expression (Fig. 3C). Indeed, we found that most 
MITF target gene expression levels were similar in both DS and TS melanomas suggesting 
that the BRAF
V600E 
mutation alone does not significantly alter the overall MITF-dependent 
transcriptome of MITF-low tumors (Fig. 3C, Supplementary Fig. S3B). In contrast, there was 
a marked increase in mitfa expression in TN growth melanomas (Fig. 3C). This change was 
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also accompanied by an increase in BRAF
V600E
 mRNA expression from the mitfa promoter in 
addition to an increase in expression of MITF target genes involved in proliferation and 
differentiation (cdk2, dct, tyr, mc1r, tyrp1a/b).  
Given that the mitfa
vc7
 mutant is a splice-site mutation, the increase in mitfa expression by 
RNA-seq might simply reflect an increase in aberrantly spliced non-functional transcripts. To 
test this, we designed primers that specifically amplified correctly spliced mitfa exons and 
found a significant increase in functional wild type mitfa transcripts in the TN melanomas 
compared with DS and TS melanomas (Fig. 3D, E). This was associated with a modest 
increase in Mitfa protein in TS melanomas, and a robust increase in Mitfa protein in the TN 
melanomas (Fig. 3F, G). Based on these data, we classified DS melanomas as MITF-low 
melanomas and TN melanomas as MITF-high melanomas. Some TS melanomas had higher 
RNA and protein levels of Mitfa, however we also classified these as MITF-low melanomas 
because they shared a strong similarity of MITF target gene expression with DS melanomas 
and clustered together by unsupervised clustering (Fig. 3C; Supplementary Fig. S3A, B). 
Further, MITF has been proposed to function as a repressor at some gene promoters (25) and 
we find de-repression of some of these genes in MITF-low melanomas, including genes 
involved in stem cell states (klf4, klf5a, klf9, erbb3) and metabolism (acsf2, apodb, mboat1) 
(Supplementary Fig. S3B). These results suggest that DS and TS MITF-low melanomas are 
transcriptionally distinct from TN MITF-high melanomas in MITF activity. 
In human melanoma, MITF gene expression is controlled by neural crest transcription factors 
including PAX3 and BRN2 (also known as POU3F2) that act in a reciprocal manner to control 
high and low MITF gene expression, respectively (26). Increased mitfa gene expression in 
BRAF
V600E
 nodular growth melanomas was accompanied by an increase in pax3a expression, 
while mitfa low expression level in BRAF
V600E
 melanomas with superficial growth was 
associated with upregulation in brn2b (pou3f2b) expression. Both pax3a and brn2b (pou3f2b) 
were down-regulated in (non-BRAF
V600E
) MITF-low p53
mut 
melanomas (DS, Fig. 3C). This 
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suggests that a Brn2b-Pax3a reciprocal mechanism might be active only in BRAF
V600E
 
melanomas and be responsible for a switch from low to high mitfa RNA expression.  
Zebrafish and human MITF-low melanomas share invasive and mesenchymal programs  
We sought to relate our findings in zebrafish melanoma to MITF-low melanomas from patients. 
We established the genes that were differentially expressed between superficial growth (low 
mitfa expression) and nodular growth (higher mitfa expression) zebrafish melanomas, and then 
compared these with the genes that were differentially expressed between 40 human TCGA 
melanomas with the lowest and 40 melanomas with the highest MITF mRNA expression (Fig. 
3H). MITF-low superficially growing zebrafish melanomas (both with or without BRAF
V600E
) 
shared marked and significant similarity to human melanomas with low MITF mRNA 
expression (Fig. 3I) such as mesenchymal and invasive programs, retinoic acid metabolic 
processes, as well as neural crest cell development, migration and differentiation signatures 
that include genes involved in stem cell and mesenchymal fates (Fig. 3I, Supplementary 
Tables S2, S5). These results show that zebrafish MITF-low melanomas model human MITF-
low transcriptional signature melanomas at the molecular level.  
Nodular growth melanomas showed less resemblance to the 40 human melanomas with the 
highest MITF mRNA expression levels, however some pathways were significantly shared 
between nodular zebrafish melanomas and human melanomas with the highest MITF RNA 
expression level, including the Lund MITF-high pigmentation cluster (Supplementary Fig. 
S4A-B, Supplementary Table S6). These data indicate that zebrafish MITF-low superficial 
growth melanomas model the TCGA MITF-low melanomas while zebrafish MITF-high nodular 
melanomas more closely align with the Lund MITF-high pigmentation melanomas at the 
transcriptional level.  
Subtype-specific transcriptional signatures stratify zebrafish melanomas 
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Next, we performed a pairwise comparison of differential mRNA expression from each 
zebrafish melanoma subtype to identify the molecular signatures that define them (Fig. 4A, 
Supplementary Table S7). DS melanomas expressed high levels of WNT and mesenchymal 
genes (Fig. 4A-D), as well as the vascular genes pdgfra and kdr that are orthologous to human 
PDGFRA and KDR and are characteristic of human Triple-WT melanomas (Supplementary 
Fig. S4C, D). Surprisingly, the TS melanomas showed upregulation of neuronal genes, 
including the neuronal gene set specifically upregulated in MITF-low TCGA transcriptional 
clusters (Fig. 4A, D). TN melanomas that were enriched for MITF program activation 
expressed proliferation genes and a neural crest formation program (Fig. 4A-D). This MITF-
high state includes expression of sox10, foxd3, pax3, and tfap2 genes, as well as crestin (a 
zebrafish neural crest marker gene) that is expressed in melanoma initiating cells in zebrafish 
BRAF
V600E
 p53
mut
 melanomas (27) (Fig. 4B-D).  
Neural crest genes were expressed in all melanoma subtypes. Nevertheless, the levels and 
gene signatures differed between them. The superficial growth melanomas expressed neural 
crest signatures that are broadly stem-like (e.g. erbb2, erbb3a/b) and mesenchymal (e.g. sox9, 
twist1a/1b/3) while the nodular growth melanomas expressed genes involved in developmental 
programs (e.g. sox10, foxd3, mitfa) (Supplementary Fig. S4E). We validated this finding using 
a zebrafish specific Sox10 antibody, and found highest Sox10 protein expression in the TN 
melanomas (Fig. 4E, F). These results indicate that more than one neural crest cell lineage 
specification program can be active in melanoma, perhaps reflecting activation of some of the 
recently described gene networks that characterize neural crest stage and fate decisions (28). 
Discovery of melanoma subpopulations resistant to MITF activity loss 
MITF is a lineage dependent oncogene (29) and we have previously demonstrated that 
BRAF
V600E
 MITF-low melanomas depend on MITF activity for survival (9). We asked whether 
our three new melanoma models presented here also depended on MITF activity for survival. 
Indeed, tumors in all three melanoma models rapidly regressed by apoptosis when MITF was 
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eliminated by switching to the restrictive temperature (32°C), and recurred at the permissive 
temperature (<26°C) (Fig. 5A, B and Supplementary Fig. S5A, B). In all fish, the melanomas 
recurred at the same sites as the initial tumor site. These experiments indicate that MITF is a 
lineage survival oncogene for the bulk of melanoma with and without BRAF
V600E 
mutations, and 
in melanomas with MITF-low or MITF-high activity. 
The dramatic loss of tumor followed by regrowth in the same site led us to hypothesize that a 
subpopulation of melanoma cells remains at the regression site and can resist loss of MITF 
activity. To address this, we crossed our melanoma prone zebrafish (TS and TN) to zebrafish 
that carry a transgene that expresses GFP from the mitfa promoter in order to follow GFP 
positive (+) cells during melanoma regression. As explained previously, we chose this mitfa 
promoter because it is not regulated by Mitfa protein, and therefore the expression of 
BRAF
V600E
 or GFP does not change as a result of altering Mitfa protein activity in our mitfa
vc7
 
conditional allele (9). We found GFP expression was clearly detected in the bulk of the 
melanoma prior to regression (Fig. 5C). 
Strikingly, despite no overt evidence of melanoma on the animal, confocal imaging revealed 
small clusters of GFP+ melanoma cells at the original tumor site following regression (Fig. 5D). 
Clusters of GFP+ cells were specific to the regression site and were not found in matched 
healthy tissue from the same animal (Fig. 5D), and non-melanoma melanocyte progenitor 
GFP+ cells were only sparsely located elsewhere on the fish skin (Supplementary Fig. S5C, 
D). Sectioning the fish at the melanoma regression site confirmed the presence of small 
clusters of GFP+ cells (Fig. 5E).  
These results show that MITF is a lineage oncogene in BRAF dependent and independent 
melanomas, and reveal subpopulations of melanoma cells that remain at the regression site 
and are resistant to MITF loss. This residual disease cell population (termed MITF-independent 
cells) likely contribute to melanoma recurrence, and may represent an important new target for 
therapeutic interventions in melanoma.   
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MITF-independent cells share gene expression signatures with human melanoma 
residual disease states     
We next sought to understand the nature of residual disease cells remaining at the tumor site 
after melanoma regression. To this end we sorted small cell clusters (<50 cells) of GFP+ cells 
from primary tumor and residual disease from superficial (TS) and nodular (TN) growth 
melanomas (Fig. 6A, Supplementary Fig. S6A, B) and generated RNA-sequencing libraries 
using the Smart-Seq2 protocol (10). Analysis of primary and regressed cell clusters showed a 
number of differentially expressed genes with significant upregulation in the primary tumor 
(Fig. 6B).  Expression of MITF target genes was strongly suppressed in melanoma cells 
residing at the regression site (Fig. 6C). Mitfa protein expression was almost undetectable at 
the regression site, while residual disease cells maintained the expression of Sox10 protein 
(Fig. 6D, E). GSEA analysis revealed that MITF-independent residual disease cells are 
enriched in mesenchymal and invasive gene expression signatures (e.g. as defined by Cheng, 
Hoek and Kandel, Supplementary Table S2-S3), and in the neural crest stem cell (NCSC) 
signature identified in residual disease following BRAF plus MEK inhibitor treatment (30) (Fig. 
6F, G; Supplementary Table S3).  
To establish whether these cell states are relevant to human melanoma, we analyzed an RNA-
Seq dataset of patients before BRAF plus MEK inhibitor treatment and following resistance 
(31,32), and found that the MITF-independent residual disease cells share similar molecular 
expression signatures with human therapy-resistant melanomas (Fig. 6G). This enrichment is 
specific for melanoma samples because matched GFP+ melanocyte progenitor cells from 
unaffected tissue of the same fish are not enriched for these gene sets (Fig. 6G). Thus, the 
MITF-independent residual disease cell state is specific to melanoma, and does not exist in 
non-melanoma melanocytes, and is not a result of the temperature-shift to turn off MITF 
activity.  
The MITF-independent cell state pre-exists in primary melanoma  
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Minimal residual disease cells are rare, and so we performed deep plate-based (Smart-Seq2) 
sequencing to investigate the residual disease state at the single cell resolution.  To investigate 
the residual disease state at the single cell resolution, we profiled the transcriptomes of 332 
GFP+ single cells from superficial (TS) and nodular (TN) growth melanomas and residual 
disease from corresponding subtypes, as well as from TN melanoma recurring disease (n= 43, 
80, 63, 61 and 85 single cells respectively, Supplementary Fig. S6C). We clustered cells 
based on similarities of their transcriptional profiles using the unsupervised Louvain algorithm 
on principal component reduction and visualised using Unifold Manifold Approximation and 
Projection (UMAP). We identified 6 clusters (numbered 0-5) (Fig. 7A). Clusters 0 and 2-5 were 
primarily composed of cells from a predominant but not exclusive single experimental condition 
(Fig. 7B). In contrast, cluster 1 contained cells from all experimental conditions revealing a cell 
state common to all melanoma subtypes and stages (Fig. 7B). 
All residual disease states had very low-to-no MITF target gene expression confirming the 
MITF-independent state of these cells. We investigated whether the MITF-independent cell 
state was specific to the residual disease cells or whether an MITF-independent state pre-
existed in the primary tumor. Strikingly, while MITF target genes were generally upregulated in 
the primary tumor cells (even at low levels) (Fig. 7C) a subpopulation of cells in the primary 
tumors showed markedly reduced MITF target gene expression (Fig. 7C), indicating that the 
MITF-independent state is already present in the primary tumors. A pre-existing MITF-
independent subpopulation was also present in melanomas and residual disease from a 
smaller additional single cell dataset we generated (Supplementary Fig. S6D, S7A, B). All 
cells continued to express sox10 perhaps as a means to bypass the dependence on MITF 
activity for survival (Fig. 7D; Supplementary Fig. S7C). Thus, while the bulk of the tumor is 
dependent on MITF activity for survival, a MITF-independent state is present as a 
subpopulation and is resistant to loss of the MITF lineage factor. 
Exclusive and shared cell states in residual and recurrent disease  
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Interestingly, we identified distinct cell populations in residual disease that were specific to 
melanoma subtype. Superficial melanoma residual disease cells (cluster 4) were enriched for 
invasive and mesenchymal genes, and expressed some of the genes of the Rambow-neural 
crest stem cell signature, compared with the superficial primary tumor (cluster 3) (Fig. 7E, 
Supplementary Fig. S7D, Supplementary Table S8). In contrast, nodular melanoma residual 
disease (cluster 5) was enriched for genes involved in purine metabolism and the neural crest 
developmental programme (Kaufman_zfin_NC; (27)) compared to the primary nodular tumor 
(cluster 0) (Fig. 7F, Supplementary Table S8). Enhanced expression of and dependency on 
nucleotide metabolism is a feature of the neural crest and melanoma (33,34). Expression of 
purine metabolism genes may represent a Sox10+ MITF-independent neural crest metabolic 
state. Alternatively, purine metabolism genes are highly expressed in xanthophores, a closely 
related zebrafish neural crest derived pigment cell type (35), and expression of purine 
metabolism pathways may represent differentiation toward this neural crest cell fate to maintain 
survival.  
Finally, we explored the cell state in nodular melanomas in the early stages of recurrence (10 
days following reactivation of Mitfa). We found recurrent melanoma cells enriched for MITF 
target genes and protein translation genes (Fig. 7G, Supplementary Table S8). Despite the 
apparent shift away from the neural crest and purine metabolism pathways expressed in 
residual disease and towards MITF pathway activity, recurrent disease did not show gene 
expression associated with the cell cycle that is present in the primary nodular melanomas 
(Fig. 7G). Thus, early recurrent disease may need to first activate MITF transcriptional and 
protein translation pathways prior to activation of a proliferative phase to contribute to tumor 
regrowth.   
Strikingly, all experimental conditions (primary, residual and recurrent disease) shared a 
common cell state (cluster 1) that expresses neural crest genes including enrichment for erbb2 
and zeb2a. Further, we found particular enrichment of genes recently described in a G0-like 
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neural stem cell state (36) such as the epigenetic factors arid1b, kmt2c, the cell cycle inhibitor 
p27 (cdkn1bb) and ribosomal components (Fig. 7H, I). Some cells in cluster 1 also express 
high levels of the melanoma slow cycling cell marker JARID1B (encoded by the kdm5ba gene 
in zebrafish) (37). These experiments show that residual disease generated through MITF loss 
leads to multiple MITF-independent cell states both exclusive and shared with primary tumors. 
Further, MITF depletion leads to a common neural crest G0-like state (NC_G0-like_ribosomal) 
that exists in primary, regressed and recurrent disease stages that may be vital for melanoma 
survival.  
 
Discussion 
Gene expression signatures defined by the TCGA and Lund subtypes are predictive for 
survival across multiple independent datasets indicating that gene expression profiling is a 
clinically relevant biomarker for patient stratification (2,4-8). Moreover, immune based 
transcriptional signatures can be predictive for response to immune therapies (38,39). Of 
particular importance, the Lund MITF-low proliferation melanoma subtype and the TCGA MITF-
low signature predicts among the worst outcomes for patients (8). However, animal models of 
melanomas defined by these transcriptional signatures are lacking in part because little is 
known about how these subtypes are established. 
Here, we have used a temperature sensitive conditional mitfa
vc7
 mutant allele to model the 
MITF-low melanoma transcriptional state. We discover that the MITF-low state is highly 
invasive (mesenchymal) and exhibits plasticity toward a proliferative MITF-high state. Further, 
we discover a shared MITF-independent cell state in residual disease that pre-exists in primary 
melanomas. Together, these cell states may partially explain the poor outcomes for patients 
with MITF-low melanomas.  
We define this MITF-low state in zebrafish by reduced levels of wild type mitfa RNA transcript 
and Mitfa protein (Fig. 3) (9,20). The zebrafish MITF-low activity results in reduced expression 
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of pigmentation genes, and shares stem and mesenchymal gene expression patterns with the 
human TCGA MITF-low and Lund MITF-low proliferation gene expression clusters. Although 
the TCGA MITF-low transcriptional signature includes expression of neuronal genes, we 
demonstrate that the MITF-low state can also be characterized by a vasculogenic signature 
uncoupled from neuronal genes (i.e. DS melanomas). Taken together, zebrafish MITF-low 
melanomas are relevant models for the human MITF-low melanoma transcriptional gene 
expression cluster.  
BRAF
V600E 
is not sufficient on its own to increase mitfa expression and many BRAF
V600E
 
positive melanomas maintain a MITF-low gene expression signature. How mitfa expression is 
significantly increased in only some BRAF
V600E
 melanomas in our zebrafish models is not 
known, but our results demonstrate that nodular growth melanomas have the potential to 
increase sox10 and mitfa RNA and protein expression, and express genes similar to the Lund 
MITF-high pigmentation subtype. We term these MITF-high
 
melanomas, and find an increase 
in wild type mitfa mRNA and Mitfa protein expression is accompanied by an increase in 
BRAF
V600E
 expression because the BRAF
V600E
 transgene is under the control of a mitfa 
promoter fragment. While we cannot differentiate between the impact of Mitfa and BRAF
V600E
 
activity on nodular growth pathology, our models reveal the important finding that the MITF-low 
state is unstable with the potential to increase mitfa and Mitfa target gene expression.  
While melanomas can express high or low levels of MITF overall, cells can be heterogeneous 
for MITF within the tumor itself (40) and cells with low MITF
 
are resistant to MAPK pathway 
inhibition (41). Single-cell RNA analysis indicates that cells that express high or low MITF RNA 
levels can coexist within an individual melanoma tumor supporting the concept that cells can 
switch their MITF transcriptional states in vivo (30,31,42-44). Our results suggest a Pax3a-
Brn2b rheostat may regulate this switch in MITF gene expression from a low to high state 
specifically in BRAF
V600E
 melanomas (26,40,45). Understanding how MITF-low melanomas 
shift to MITF-high melanomas, and vice versa, is important because the Lund MITF-low 
proliferation transcriptional signature is enriched in melanomas post therapy and this state 
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confers intrinsic and acquired resistance to MAPK pathway inhibition in cell lines and in patient 
tumors (5,41). Notably, patients can relapse on targeted therapy with individual melanoma 
clones that are both MITF-high and MITF-low, underscoring the importance of the 
transcriptional state switch in patients (41).  
Our work shows that neural crest programs are active in both the superficial and nodular 
growth subtypes, but that the neural crest signatures that characterize the superficial growth 
melanomas (MITF-low melanomas) are enriched in mesenchymal and invasive genes (e.g. 
sox9b, twist 1a/b/3) while nodular growth melanomas (MITF-high melanomas) are enriched in 
developmental program genes (e.g. mitfa, sox10, foxd3, pax3a). Recent single cell RNA-
sequencing studies of the mouse neural crest reveal early migratory transcriptional states 
followed by branched fate transcriptional trajectories that co-express bipotent cell fates prior to 
fate commitment (46). While these states are not as markedly defined in our melanomas as 
found in development, our results extend the understanding of neural crest pathways in 
melanoma by showing that more than one neural crest gene expression program can be active 
depending on melanoma subtype. 
MITF activity is considered a drug target because MITF is a lineage survival oncogene and 
turning off MITF activity has little impact upon other cell types (29). Regression followed by 
recurrence in our zebrafish MITF on-off-on models has similarities to the regression and 
recurrence of patient tumors following BRAF inhibitor therapy in which both diseases progress 
through undetectable minimal residual disease. Through live imaging and 
immunohistochemistry of zebrafish at the melanoma regression site, we visualized small cell 
clusters of residual disease. Our model predicts these cell populations would be resistant to 
MITF inhibitors. Further, it seems likely that these cells contribute to disease recurrence, 
although we cannot exclude that other melanoma cells exist at the regression site that do not 
express GFP and may be transformed in the context of the tumor regression micro-
environment for expansion and growth (for example as reported in (47)). Lineage-tracing 
studies in this model system, and more broadly in the study of residual disease, will be critical 
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to determine which cells at the residual disease site maintain malignancy and contribute to 
disease relapse. 
Our results here show that residual disease has very low-to-no MITF transcriptional activity, 
very low-to-undetectable Mitfa protein and is resistant to MITF as a lineage survival oncogene. 
Recently, Rambow and colleagues (30) identified four subpopulations of cells in residual 
disease following BRAF and MEK inhibitor treatment including invasive cells and NCSCs with 
"very low to undetectable" expression of MITF
 
or its target genes. MITF-independent cells 
express genes that are enriched for the invasive and NCSC states indicating that these 
signatures can define both the BRAF plus MEK inhibitor resistant cells and MITF-independent 
cells. One explanation for this result is that MAPK pathway inhibitors lead to the direct loss of 
MITF activity in residual disease, and therefore resemble the same cell state as experimental 
loss of MITF as seen in our models. An alternative explanation is that tumor regression itself 
(caused by BRAF/MEK inhibitors or MITF loss) changes the microenvironment such that the 
extant MITF-independent subpopulation undergoes a transcriptional shift toward 
invasive/NCSC programs (e.g. TS residual disease), or even toward differentiation programs 
(e.g. TN residual disease) depending on the primary tumor subtype.  
The MITF-independent state that is shared between all disease conditions (cluster 1) maintains 
expression of neural crest markers sox10 and foxd3 with specific enrichment of erbb2 and 
zeb2a. Further, cluster 1 shows up-regulation of ribosomal genes together with the cycle cell 
inhibitor p27 (cdkn1bb) and arid1b which together are enriched in a G0-like state (36). Notably, 
a few cells in cluster 1 strongly express the slow-cycling cell gene jarid1b (kdm5ba) (37). This 
G0-like state may have important clinical implications for patients because G0-like cells can be 
enriched following therapy (48) and have been reported to require JARID1B to exert a stem 
cell-like function (49). Lineage tracing experiments will be important to directly test if the extant 
cluster 1 cells in the primary tumor are the same cells in residual disease, and how they 
contribute to recurrent disease. Future cell transplantation studies will enable the 
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characterization of phenotypic differences among residual disease cell subpopulations, such as 
tumor initiation or invasion potential, or differentiation states.  
In summary, our results prove the MITF-low transcriptional signature reflects an underlying 
biological state and reveals melanoma transcriptional heterogeneity within this subtype which 
may contribute to poor outcomes for patients. Further, given MITF is an important drug target 
we reveal an extant melanoma cell subpopulation that resists loss of MITF activity and may 
contribute to disease perdurance. Some of the MITF-independent residual disease may be 
sensitive to therapy. For example, RXR-gamma inhibitors can target melanoma cells in the 
NCSC state (30) and mitochondrial respiration inhibitors can target the slow-cycling 
JARID1B
High
 cells (50). Our work shows further complexity for the targeting of residual disease 
because we find residual disease states that are shared by all disease stages and those that 
are exclusive to tumor subtype. These findings underscore the importance of targeting both the 
bulk of the tumor and residual disease cells for long-term survival outcomes. 
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Figure legends 
Fig. 1. MITF-low activity and p53 mutations co-operate in melanoma 
A. Graphical overview of MITF activity based on temperature changes in mitfa
vc7
 mutant 
fish compared to wild type. 
B. Pie chart of MITF-low melanoma subtypes and associated mutations in TCGA 
cutaneous melanoma samples. 
C. Images of wild type, mitfa
vc7
 mutant, mitfa
vc7
; p53
M214K
 double mutant and 
Tg(mitfa:BRAF
V600E
); mitfa
vc7
; p53
M214K
 zebrafish at different temperatures. At 25°C 
(permissive conditions), wild-type fish show normal stripe pattern, while mitfa
vc7
 fish 
show reduced pigmentation (green arrow). mitfa
vc7
; p53
M214K
 fish develop pigmented 
(black) melanomas (black arrow) and Tg(mitfa:BRAF
V600E
); mitfa
vc7
; p53
M214K 
develop 
unpigmented (blue arrow) and pigmented (black and red arrows) melanomas. 
D. Survival curves for mitfa
vc7
 (green), p53
M214K 
(dark blue), mitfa
vc7
; p53
M214K
 (red) and 
Tg(mitfa:BRAF
V600E
); mitfa
vc7
; p53
M214K  
(light blue) zebrafish. ****p<0.0001 (Log-rank 
test). 
E. Bar chart showing percentage of pigmented, unpigmented and both melanoma types.  
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Fig. 2. Superficial and nodular growth melanomas are highly invasive  
A. H&E stained sections of mitfa
vc7
; p53
M214K
 (double superficial, DS) and 
Tg(mitfa:BRAF
V600E
); mitfa
vc7
; p53
M214K
 (triple superficial, TS, triple nodular, TN 
pigmented and unpigmented). Scale bar = 1 mm. 
B. Close-up H&E images of the surface area of melanoma, scale bar = 50 µm. 
C. Close-up H&E images of the invasive component of melanoma, scale bar = 20 µm. 
D. Drawing showing the experimental approach for quantification of melanoma invasion 
depth (left, red lines; quantified in E) and width of invasion stream at the edge of 
invasion (right, yellow box left and black lines with arrows; quantified in F), blue dashed 
lines follow invasive edge. 
E. Dot-boxplot showing the invasion depth calculated as ratio between melanoma 
thickness (a) and distance to the midline (b). ns= not significant (Dunn test), n=4 (DS, 
TS) and 5 (TN) fish. 
F. Dot-boxplot showing the cell stream width at the invasion edge measured as distance 
between two neighboring muscles (average of 5 measures per fish); ns = not 
significant, **p<0.01 (Dunn test), n=4 (DS, TS) and 5 (TN) fish.    
G. Immunohistochemistry (DAB staining) of mitfa
vc7
;p53
M214K
 superficially growing (left) 
and invasion (right) parts of bleached melanoma sections, stained with anti-phospho-
ERK antibody. Unbleached corresponding H&E section in H shows no pigmentation in 
the invasive component; scale bar = 50μm. See also Supplementary Fig. S1.  
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Fig. 3. MITF-low melanomas model human melanomas with low MITF expression 
A. Schematic of zebrafish melanoma phenotypes used for whole tumor bulk RNA-seq. 
B. Principal component analysis plot showing three separate clusters of primary 
melanomas, mitfa
vc7
; p53
M214K
 (double superficial, DS) and two clusters for 
Tg(mitfa:BRAF
V600E
); mitfa
vc7
; p53
M214K
 (triple superficial, TS and triple nodular, TN); 
ellipse represents 95% confidence interval (multivariate t-distribution). 
C. Heat map of gene expression for mitfa, pax3a, pou3f2b (brn2b), human BRAF
V600E
 
transgene and MITF target genes (as defined in Hoek et al., 2008). 
D. Schematic of mitfa pre-mRNA with the vc7 mutation indicated. Location of aberrant 
splicing changes (red asterisk) and qPCR-product of correctly spliced variant (grey and 
yellow line) are indicated. 
E. Dot-boxplot showing qPCR of the mitfa correctly spliced variant using two sets of 
primers (exon 6-7, grey; exon 5-7, yellow). **p<0.01 (Dunn test). 
F. Representative images showing IF-IHC staining of Mitf protein across different 
melanoma subtypes counterstained with DAPI. Scale bar = 20 µm. 
G. Violin dotplot showing Mitf nuclear fluorescence intensity normalized to the size of 
nucleus (Corrected Total Cell Fluorescence; CTCF). Each dot represents one nucleus, 
n=4 fish per condition. **** p< 0.0001 (Dunn test).  
H. Differential expression analysis between superficial and nodular zebrafish melanomas 
compared to differential expression analysis between 40 patients with lowest MITF and 
highest MITF expression. Venn diagrams of shared upregulated genes (left) and 
shared pathways (right) (p<0.05, Benjamini-Hochberg = BH test). ****p<0.0001 
(hypergeometric distribution with Holm correction). 
I. Selection of 11 pathways from the Venn diagram intersect is shown in the dotplot (GO-
BP, KEGG and literature based). Dot size represents the fold enrichment of the 
pathway compared to expected expression. Color shows adjusted p-value (BH test). 
See also Supplementary Tables S2, S5-S6 and Supplementary Figs. S2-S4. 
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Fig. 4.  Transcriptional sub-clusters define MITF-low and MITF-high melanomas  
A. Dot plot of pathway analysis showing a selection of significant pathways (GO-BP, 
KEGG and literature based – Supplementary Table S2) in a pairwise comparison 
between melanoma model clusters. Dot size represents the fold enrichment of the 
pathway compared to expected expression. Color shows adjusted p-value (Benjamini-
Hochberg test = BH). DS=double superficial, TS = triple superficial, TN = triple nodular  
B. Violin plots showing examples of differences in neural crest markers expression 
(sox10, crestin) and Wnt pathway (wnt7aa, tcf7l2) followed by their validation by qPCR 
using the same samples used for RNA-seq. ns= not significant, * p < 0.05, **** p < 
0.0001, BH test. 
C. Violin plots showing validation by qPCR of genes from B using the same samples used 
for RNA-seq, ns= not significant, * p < 0.05, ** p < 0.01, Dunn test. 
D. Schematic of zebrafish melanoma classification with a heatmap of five selected genes 
of a pathway(s) specific for the cluster (red=high, blue=low). 
E. Representative images showing IF-IHC staining of Sox10 protein across different 
melanoma subtypes counterstained with nuclear marker (DAPI). Scale bar = 20 µm. 
F. Violin dotplot showing Sox10 nuclear fluorescence intensity normalized to the size of 
nucleus (Corrected Total Cell Fluorescence, CTCF). Each dot represents one nucleus, 
n=4 fish per condition. **** p< 0.0001 (Dunn test).  
See also Supplementary Table S7 and Supplementary Fig. S4. 
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Fig. 5. Imaging of residual disease cells at the site of melanoma regression 
A. Representative images of zebrafish with melanoma at <26°C, after 2 month upshift to 
32°C to regress the tumor followed by a 1 month downshift back to <26°C for tumor 
regrowth. 
B. Line graphs of four zebrafish showing tumor size over time during regression and 
recurrence.  
C. Brightfield and fluorescence images of zebrafish with melanoma in the head region at 
<26°C and 2 months after upshift to 32°C. Black arrows indicate melanoma before and 
after regression. White squared box indicate residual disease cells enlarged in D. 
D. Representative images of standard deviation intensity projection of confocal z-stack 
acquisition of the melanoma regression site (white square box region (C); left) and 
healthy tissue from the same fish (right). White arrows point to the residual GFP+ cells, 
scale bar = 100 μm, n = 6 fish. 
E. Histopathology image shows DAB immunohistochemistry on a bleached transverse 
section of the fish after 2 months at 32°C and stained with anti-GFP antibody. The 
black box is enlarged to show the staining in more detail. One of the cell clusters 
stained in brown is highlighted in square box and displayed at higher magnification to 
the right. Black arrows depict GFP positive clusters. B – brain, e – eye; scale bars = 
100 μm and 10 μm. See also Supplementary Fig. S5. 
  
34 
 
Fig. 6. MITF-independent cells mark residual disease and show decrease in Mitfa activity 
A. Schematic of low input Smart-seq2 RNAseq design for cells at the regression site, in 
matched healthy tissue and in the primary tumor. 
B. Volcano plot shows differentially expressed genes in primary and regressed 
melanomas with color change denoting genes with FDR<0.05 (Benjamini-Hochberg 
test). Orange dots indicate significant genes expressed in the primary tumor, green 
dots denote significant genes in regressed tissue. 
C. Enrichment plot showing decrease of MITF target genes expression in regressed tumor 
compared to primary melanoma with NES=1.60 and FDR=0.05 (Kolmogorov–Smirnov= 
KS test). 
D. Representative images showing IF-IHC staining of Mitfa protein in primary tumor and 
regression site (=Reg) counterstained with nuclear marker (DAPI). White arrows point 
to very low-to-no Mitfa expressing cells at residual disease. Scale bar = 20 µm, n=4 
fish.  
E. Representative images showing IF-IHC staining (of consecutive section to D) of Sox10 
protein between primary tumor and regression site counterstained with nuclear marker 
(DAPI). Scale bar = 20 µm, n=4 fish.  
F. Enrichment plots of Mesenchymal (NES=-1.93) and NCSC (NES=-1.82) signatures 
specifying genes that are enriched at the regression site relative to the primary tumor. 
FDR: Mesenchymal = 0.004, NCSC = 0.01 (KS test). 
G. Heatmap showing the average log2 fold change of genes defining pathways 
(Supplementary Table S3) within primary and regressed tumors relative to overall 
average values across all samples – primary, regressed tissue and matched unaffected 
tissue from regressed fish. The same analysis was performed for pre and post BRAFi 
and MEKi treatment patients and merged into one heatmap.  
See also Supplementary Figs. S6-S7 and Supplementary Tables S2-S3. 
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Fig. 7. Single cell analysis shows distinct and shared cell states in residual disease 
A. Uniform Manifold Approximation and Projection (UMAP) of primary, regressed and 
recurring GFP+ positive melanoma single cells (n=332 cells) showing 6 different 
clusters. 
B. UMAP representation of A highlighting the origin of the single cells: primary superficial 
(blue), primary nodular (red), regressed superficial (purple), regressed nodular (yellow) 
and recurring nodular (green). Grey dotted line shows cluster 1 containing a mix of 
origins. 
C. UMAP representation of A based on the AUC scores of MITF target genes (Hoek et al., 
2008) indicated with color change from blue (negative) to orange (positive). 
D. UMAP representation of A with color change from grey (negative) to red (positive) 
based on log10 mRNA expression of sox10. 
E-G. Dot plots of pathway analysis show a selection of upregulated significant pathways in 
clusters with predominant regressed or recurring populations. From left to right: cluster 
4 (E), cluster 5 (F) and cluster 2 (G). Dot size represents the fold enrichment of the 
pathway compared to expected expression. Color shows adjusted p-value (BH test). 
H. UMAP representation from A with color change from grey (negative) to red (positive) 
based on the AUC scores of selected genes (denoted as NC_G0-like_ribosomal gene 
set) highlighted in red dashed rectangle in I. 
I. Dot plot of selected genes showing average expression among the clusters, with 
cluster 1 highlighted by grey dotted box. Red dashed rectangle denotes genes used for 
NC_G0-like_ribosomal gene set shown in H. Dot size corresponds to the percentage of 
expressing cells within the cluster. 
See also Supplementary Figs. S6-S7 and Supplementary Tables S2 and S8. 
 







